Durvalumab + Gemcitabine + Cisplatin
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Intrahepatic Cholangiocarcinoma
Conditions
Advanced Intrahepatic Cholangiocarcinoma
Trial Timeline
Jun 10, 2025 → Nov 19, 2030
NCT ID
NCT06858735About Durvalumab + Gemcitabine + Cisplatin
Durvalumab + Gemcitabine + Cisplatin is a phase 2 stage product being developed by AstraZeneca for Advanced Intrahepatic Cholangiocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06858735. Target conditions include Advanced Intrahepatic Cholangiocarcinoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Intrahepatic Cholangiocarcinoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06858735 | Phase 2 | Recruiting |
| NCT06611345 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Advanced Intrahepatic Cholangiocarcinoma